Abstract | OBJECTIVE: BACKGROUND: DESIGN/METHODS: Twenty-four adults, aged 27 through 76, with either hypertension or prehypertension, were included in this open-label study. Participants suffered from migraines (diagnosed according to International Headache Society classifications) for at least 3 months. Patients were treated with 10 to 40 mg of olmesartan per various observational periods of at least 3 months. Frequency and severity were recorded by office visits or by telephonic interview. RESULTS: Patients reported an 82.5% average reduction in the frequency of migraine attacks. Patients also experienced a 45% average reduction in the severity of migraine attacks measured on a numeric pain scale of 1 to 10. The only undesired effect was dizziness or presyncope. No serious adverse events occurred and no adverse event caused a premature termination. Two patients had no reduction in headache frequency, intensity, and blood pressure. CONCLUSIONS:
|
Authors | James A Charles, Seymour Jotkowitz, Lawrence H Byrd |
Journal | Headache
(Headache)
Vol. 46
Issue 3
Pg. 503-7
(Mar 2006)
ISSN: 0017-8748 [Print] United States |
PMID | 16618270
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Imidazoles
- Tetrazoles
- olmesartan
|
Topics |
- Adult
- Aged
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Cross-Over Studies
- Double-Blind Method
- Female
- Humans
- Hypertension
(complications)
- Imidazoles
(therapeutic use)
- Male
- Middle Aged
- Migraine Disorders
(prevention & control)
- Tetrazoles
(therapeutic use)
|